We and others recently determined that niclosamide, a Food and Drug Administration‐approved anthelmintic drug,16 effectively suppresses the activation, nuclear translocation and transactivation of STAT3.17, 18 However, the further clinical development of niclosamide for cancer therapy is hindered by its poor water solubility and low oral bioavailability. Here, STAT3 is linked to cancer.